Enlivex Therapeutics Ltd
ENLV0.835USD
+0.003+0.40%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
20.28MMarket Cap
LossP/E TTM
More Details of Enlivex Therapeutics Ltd Company
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Enlivex Therapeutics Ltd Info
Ticker SymbolENLV
Company nameEnlivex Therapeutics Ltd
IPO dateJul 30, 2014
CEOHershkovitz (Oren)
Number of employees36
Security typeOrdinary Share
Fiscal year-endJul 30
Address14 Einstein St.
CityNESS-ZIONA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code7403618
Phone97286623301
Websitehttps://www.enlivex.com/
Ticker SymbolENLV
IPO dateJul 30, 2014
CEOHershkovitz (Oren)
Company Executives of Enlivex Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
858.77K
+10.95%
Prof. Dror Mevorach, M.D.
Prof. Dror Mevorach, M.D.
Founder, Chief Scientific Officer and Medical Officer
Founder, Chief Scientific Officer and Medical Officer
242.34K
+3.28%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
181.46K
+1.07%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
6.41K
+241.84%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
5.29K
+56.84%
Dr. Brian Schwartz, M.D.
Dr. Brian Schwartz, M.D.
Director
Director
1.83K
+100.00%
Mr. Matteo Renzi
Mr. Matteo Renzi
Director
Director
--
--
Mr. Sangwoo Lee
Mr. Sangwoo Lee
Director
Director
--
--
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Director
Director
--
--
Dr. Oren Hershkovitz, Ph.D.
Dr. Oren Hershkovitz, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
858.77K
+10.95%
Prof. Dror Mevorach, M.D.
Prof. Dror Mevorach, M.D.
Founder, Chief Scientific Officer and Medical Officer
Founder, Chief Scientific Officer and Medical Officer
242.34K
+3.28%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
181.46K
+1.07%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
6.41K
+241.84%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
5.29K
+56.84%
Dr. Brian Schwartz, M.D.
Dr. Brian Schwartz, M.D.
Director
Director
1.83K
+100.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Novik (Shai A)
0.36%
Citizens Financial Group, Inc.
0.10%
Havron (Abraham)
0.08%
Morgan Stanley Smith Barney LLC
0.07%
Renaissance Technologies LLC
0.07%
Other
99.32%
Shareholders
Shareholders
Proportion
Novik (Shai A)
0.36%
Citizens Financial Group, Inc.
0.10%
Havron (Abraham)
0.08%
Morgan Stanley Smith Barney LLC
0.07%
Renaissance Technologies LLC
0.07%
Other
99.32%
Shareholder Types
Shareholders
Proportion
Individual Investor
0.47%
Investment Advisor
0.23%
Hedge Fund
0.11%
Venture Capital
0.02%
Research Firm
0.02%
Other
99.15%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
42
2.79M
13.33%
--
2025Q3
45
2.83M
13.82%
+229.71K
2025Q2
43
2.60M
14.07%
-610.38K
2025Q1
42
3.21M
15.05%
-376.03K
2024Q4
41
3.45M
11.66%
+845.42K
2024Q3
36
4.03M
17.19%
+480.64K
2024Q2
40
3.56M
10.88%
+1.76M
2024Q1
39
1.80M
11.54%
-369.12K
2023Q4
42
1.66M
11.85%
-69.18K
2023Q3
42
1.73M
12.24%
-44.85K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Novik (Shai A)
858.77K
3.54%
+84.74K
+10.95%
Mar 31, 2025
Havron (Abraham)
181.46K
0.75%
+1.92K
+1.07%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
219.15K
0.9%
-10.58K
-4.61%
Jun 30, 2025
Renaissance Technologies LLC
168.39K
0.69%
-12.90K
-7.11%
Jun 30, 2025
Hershkovitz (Oren Ph.D.)
42.05K
0.17%
+16.55K
+64.92%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Enlivex Therapeutics Ltd?
The top five shareholders of Enlivex Therapeutics Ltd are:
Novik (Shai A) holds 858.77K shares, accounting for 3.54% of the total shares.
Havron (Abraham) holds 181.46K shares, accounting for 0.75% of the total shares.
Morgan Stanley Smith Barney LLC holds 219.15K shares, accounting for 0.90% of the total shares.
Renaissance Technologies LLC holds 168.39K shares, accounting for 0.69% of the total shares.
Hershkovitz (Oren Ph.D.) holds 42.05K shares, accounting for 0.17% of the total shares.
Novik (Shai A) holds 858.77K shares, accounting for 3.54% of the total shares.
Havron (Abraham) holds 181.46K shares, accounting for 0.75% of the total shares.
Morgan Stanley Smith Barney LLC holds 219.15K shares, accounting for 0.90% of the total shares.
Renaissance Technologies LLC holds 168.39K shares, accounting for 0.69% of the total shares.
Hershkovitz (Oren Ph.D.) holds 42.05K shares, accounting for 0.17% of the total shares.
What are the top three shareholder types of Enlivex Therapeutics Ltd?
The top three shareholder types of Enlivex Therapeutics Ltd are:
Novik (Shai A)
Citizens Financial Group, Inc.
Havron (Abraham)
Novik (Shai A)
Citizens Financial Group, Inc.
Havron (Abraham)
How many institutions hold shares of Enlivex Therapeutics Ltd (ENLV)?
As of 2025Q4, 42 institutions hold shares of Enlivex Therapeutics Ltd, with a combined market value of approximately 2.79M, accounting for 13.33% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.48%.
What is the biggest source of revenue for Enlivex Therapeutics Ltd?
In --, the -- business generated the highest revenue for Enlivex Therapeutics Ltd, amounting to -- and accounting for --% of total revenue.
